文献速递血栓与止血

凝血因子VIII在体内调节血管性血友病因子稳态

Coagulation factor VIII regulates von Willebrand factor homeostasis invivo.
PubMed 文献 · J Thromb Haemost · 2023-09-17

本研究通过小鼠模型、重组FVIII输注及接受免疫耐受诱导治疗或艾美赛珠单抗治疗的血友病A患者,探讨FVIII对VWF蛋白水解和稳态的影响。结果显示,输注重组B结构域缺失FVIII可显著降低野生型小鼠血浆VWF多聚体大小及抗原水平,该效应部分依赖ADAMTS-13,且在血友病A小鼠和患者中亦观察到VWF多聚体大小显著降低。结论表明FVIII作为辅因子在多种病理生理条件下调控VWF蛋白水解和稳态。

要点

  • 输注重组B结构域缺失FVIII可显著降低野生型小鼠血浆VWF多聚体大小及抗原水平。
  • 在Adamts13-/-小鼠中,任何剂量BDD-FVIII均未改变VWF抗原水平,提示部分依赖ADAMTS-13。
  • 接受免疫耐受诱导治疗的血友病A患者血浆VWF多聚体大小显著降低。

核心结论

  • FVIII作为辅因子在多种病理生理条件下调控VWF蛋白水解和稳态。

研究设计与样本

  • 研究纳入小鼠模型、重组FVIII输注以及接受高剂量FVIII免疫耐受诱导治疗或艾美赛珠单抗治疗的血友病A患者。

主要发现

  • 向野生型小鼠静脉输注重组B结构域缺失FVIII(40和160 μg/kg)显著降低血浆VWF多聚体大小及抗原水平。
  • 向Adamts13+/-和Adamts13-/-小鼠输注高剂量而非低剂量BDD-FVIII也显著降低VWF多聚体大小。
  • 向Adamts13-/-小鼠给予任何剂量BDD-FVIII后血浆VWF抗原水平保持不变,提示FVIII增强的VWF降解部分依赖ADAMTS-13。
  • 通过AAV8载体在血友病A小鼠中持续表达BDD-FVIII(约50至250 U/dL)也导致血浆VWF多聚体大小和抗原水平显著降低。
  • 接受重组或血浆来源FVIII免疫耐受诱导治疗的血友病A患者血浆VWF多聚体大小显著降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Coagulation factor VIII (FVIII) and von Willebrand factor (VWF) circulate as a noncovalent complex, but each has its distinct functions. Binding of FVIII to VWF results in a prolongation of FVIII's half-life in circulation and modulates FVIII's immunogenicity during hemophilia therapy. However, the biological effect of FVIII and VWF interaction on VWF homeostasis is not fully understood. OBJECTIVES: To determine the effect of FVIII in VWF proteolysis and homeostasis in vivo. METHODS: Mouse models, recombinant FVIII infusion, and patients with hemophilia A on a high dose FVIII for immune tolerance induction therapy or emicizumab for bleeding symptoms were included to address this question. RESULTS: An intravenous infusion of a recombinant B-domain less FVIII (BDD-FVIII) (40 and 160 μg/kg) into wild-type mice significantly reduced plasma VWF multimer sizes and its antigen levels; an infusion of a high but not low dose of BDD-FVIII into Adamts13+/- and Adamts13-/- mice also significantly reduced the size of VWF multimers. However, plasma levels of VWF antigen remained unchanged following administration of any dose BDD-FVIII into Adamts13-/- mice, suggesting partial ADAMTS-13 dependency in FVIII-augmented VWF degradation. Moreover, persistent expression of BDD-FVIII at ∼50 to 250 U/dL via AAV8 vector in hemophilia A mice also resulted in a significant reduction of plasma VWF multimer sizes and antigen levels. Finally, the sizes of plasma VWF multimers were significantly reduced in patients with hemophilia A who received a dose of recombinant or plasma-derived FVIII for immune tolerance induction therapy. CONCLUSION: Our results demonstrate the pivotal role of FVIII as a cofactor regulating VWF proteolysis and homeostasis under various (patho)physiological conditions.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Cao W, Trask AR, Bignotti AI, et al. Coagulation factor VIII regulates von Willebrand factor homeostasis invivo. J Thromb Haemost. 2023. PMID: 37726033. doi:10.1016/j.jtha.2023.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。